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control, respectively. Pharmacokinetic modeling of the data revealed that IDOL is generated in two different compartments, besides the tissue compartment characterized by saturable uptake, also the compartment that accounts for the quasi-instantaneous initial distribution process is involved. The efflux rate constant of IDOL, k 21,IDOL, was much smaller than that of IDA. Rutin and phenobarbital significantly reduced IDOL production. Additionally, phenobarbital competitively inhibited the saturable uptake of both IDA and IDOL (increase in apparent Michaelis constants). Reanalysis of data obtained in previous experiments showed that Pglycoprotein inhibitors (verapamil and amiodarone) reduced IDOL uptake in a similar way as already shown for IDA. The present study further supports the utility of pharmacokinetic modeling in identifying sites of drug interactions within the heart. Idarubicin (IDA 1 ) and related anthracycline antibiotics are among the most powerful anticancer drugs (e.g., Weiss, 1992; Toffoli et al., 2000) . However, the irreversible cardiotoxicity of anthracyclines limits their therapeutic use (e.g., Keefe, 2001) . A variety of mechanisms have been suggested to explain the cardiotoxicity of anthracyclines. Thus, evidence has been provided that the intramyocardial formation of secondary alcohol metabolites is an important contributor to cardiotoxicity of anthracyclines like doxorubicin and IDA (Olson and Mushlin, 1990; Cusack et al., 1993; Minotti et al., 1995; Minotti et al., 2001) . IDA is reduced to its C13-dehydroderivative idarubicinol (IDOL) by cytoplasmic NADPH-dependent aldoketo or carbonyl reductases (Loveless et al., 1978; . New insights were obtained on cardiac carbonyl reductase by investigating doxorubicin metabolism in an in vitro human heart system (Licata et al., 2000) and in transgenic mice with heart-specific expression of human cardiac carbonyl reductase , respectively. Although the evaluation of efficient inhibitors of anthracycline reductases has been suggested as one potential strategy to optimize cardioprotection (Minotti et al., 1998) , quantitative information on the effect of carbonyl reductase inhibitors like rutin and phenobarbital (Behnia and Boroujerdi, 1999) on the kinetics of alcohol metabolite formation in the intact heart is lacking.
The amount of IDOL generated from IDA has been previously determined in the isolated perfused rat heart (Platel et al., 1999; Kang and Weiss, 2001 ). However, the cardiac pharmacokinetics of IDOL (i.e., its formation, transport and disposition in the intact heart, is still poorly understood). One aspect of studies on intact organs is that direct measurements of intramyocardial drug concentrations are difficult to perform; the functional characterization of cardiac IDOL kinetics and its localization requires a mathematical model. We recently developed a compartmental model that is capable of describing the uptake and disposition kinetics of IDA in the isolated rat heart for a 10 min infusion profile (Weiss and Kang, 2002) . The concentrationdependent uptake, along with the temperature-dependent transport (Kang and Weiss, 2003) suggested the presence of a specific mechanism that could be described by Michaelis-Menten-type kinetics.
The present study was undertaken 1) to extend this model by inclusion of the production and disposition kinetics of IDOL, 2) to analyze venous outflow curves of IDA and IDOL following infusion of IDA, 3) to investigate the effect of the carbonyl reductase inhibitors rutin and phenobarbital on the conversion of IDA to IDOL in the heart, and 4) to apply this model to previously published data to examine the influence of P-glycoprotein (P-gp) inhibitors verapamil and amiodarone on the myocardial kinetics of IDOL (Weiss and Kang, 2002) . The combined model approach uses kinetic analysis of both IDA and IDOL kinetics to estimate the parameters describing the formation and disposition of IDOL in the heart. Since IDOL is more hydrophilic than IDA, its efflux kinetics is of special interest in view of a facilitated retention in myocardium.
Materials and Methods
Materials. Idarubicin was purchased from Pharmacia and Upjohn (Erlangen, Germany) and rutin and phenobarbital from Sigma-Aldrich (Deisenhofen, Germany). Idarubicinol was kindly donated by Pharmacia and Upjohn. All other chemicals and solvents were of the highest grade available.
Perfused Rat Heart. The experiments were performed by using an isolated perfused rat heart preparation previously described (Kang and Weiss, 2001) . Briefly, adult male Sprague-Dawley rats, 300 -350g, were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally). Following the onset of general anesthesia, heparin (500 IU) was injected into the tail vein, and a cannula is bound into the trachea for ventilation. The chest was opened and an aortic cannula filled with perfusate was rapidly inserted into the aorta to prevent ischemia. Retrograde perfusion was started with an oxygenated KrebsHenseleit buffer solution, pH 7.4, containing NaCl (118 mM), KCl (4.7 mM), CaCl 2 (2.52 mM), MgSO 4 (1.66 mM), NaHCO 3 (24.88 mM), KH 2 PO 4 (1.18 mM), Glucose (5.55 mM), and Na-pyruvate (2.0 mM). It was continueously bubbled with 95% O 2 to 5% CO 2 and maintained at 37°C. The pulmonary artery was incised to allow outflow of the perfusate. Coronary perfusion was initiated through a short cannula in the aortic root and maintained at a constant pressure of 60 mm Hg in a single pass way by the Langendorff technique. The flow was controlled by a roller pump. A latex balloon was placed in the left ventricle and connected to a pressure transducer line. The balloon was inflated with water to create a diastolic pressure of 5 to 6 mm Hg. After stabilization, the system was changed to constant flow condition maintaining a coronary flow of 9.5 Ϯ 0.4 ml/min. The hearts were beating spontaneously at an average rate of 300 beats/min. Coronary perfusion pressure, the left ventricular pressure, and heart rate were measured continuously, and a physiological recording system (Hugo Sachs Elektronik, March-Hugstetten, Germany) was used to monitor left ventricular systolic pressure ( Experimental Protocol. After the stabilization for 20 min, 0.5 ml of IDA (1 mg/ml) was infused for 1 min in the absence (n ϭ 5, Kang and Weiss, 2001) and presence of the carbonyl reductase inhibitors, rutin (10 M, n ϭ 5) or phenobarbital (100 M, n ϭ 5). The doses of rutin and phenobarbital were below the threshold values that lead to changes in the measured cardiovascular effects. Outflow samples were collected every 10 s for 3 min, every 30 s for the next 7 min, every 60 s for the next 10 min, and every 5 min for the next 60 min (total collection period 80 min). These samples and hearts were assayed for IDA and IDOL by high-pressure liquid chromatography as previously described (Kang and Weiss, 2001) .
Modeling. We started data analysis using the compartmental model, which describes IDA disposition for the 10-min infusion experiment (Weiss and Kang, 2002) to the outflow data of IDA measured for the injection of 0.5 mg IDA in 1 min. Since only the kinetic data were fitted, the model could be simplified by replacing the (intracellular) saturable transport process from Compartment 2 to Compartment 3 by a passive one [i.e., rate constant k 23 (Kang and Weiss, 2003) ]. The structure of the model and the parameters accounting for the disposition of IDA were then fixed in fitting an extended model to the outflow concentration profile of the formed IDOL. Thereby, we used the ADAPT II software package (D'Argenio and Schumitzky, 1997) and a modeling methodology that has been described in detail previously (Weiss and Kang, 2002) . Since especially for nonlinear systems the information content of one experiment may be insufficient to resolve the parameters into a unique set of most probable values, we took advantage of the fact that three data sets stem from different but related experiments, the modeling function of which shares one or more parameters. Thus, simultaneous nonlinear regression was performed using three data sets, the average data of the control group (Kang and Weiss, 2001 ) and those of the rutin and phenobarbital groups. The parameters described the kinetics in the control group and factors f i accounted for a potential change in parameters P i due to the treatments (i.e., in the model of the treatment groups, model parameters P i were replaced by f i P i ). All possible combinations of factors were tested with the aim to describe treatment groups by a minimum number of factors (i.e., free model parameters). The model selection was made according to the following criteria. Any model showing a noninvertible Fisher's information matrix was discarded as nonidentifiable (Landaw and DiStefano, 1984) . The comparison between the different fittings to a set of data were performed by means of visual examination of the distribution residuals and Akaike Information Criterion (Ludden et al., 1994) and fractional standard deviations of parameter estimates (FSD). We considered an FSD Ͼ 50% to indicate that a parameter has not been estimated with sufficient statistical certainty.
To reduce possible bias in the final parameter estimates due to the choice of the starting values, each curve was independently fitted 10 times using randomized starting values for the parameters to be optimized. The structure of the finally selected minimal compartmental model consists of seven compartments, four and three for the disposition of IDA and IDOL, respectively (Fig.  1) . The model corresponds to the following set of differential equations that describe changes in the compartmental amounts of IDA (eqs. 1-3) and the formed IDOL (eqs. 4 and 5):
Compartment IDA 1 with apparent initial distribution volume (V 1 ) represents the vascular space and rapidly equilibrating tissue region; both perfusate flow (Q) and IDA input rate (R IDA ) occur into this compartment. Note that the Compartments IDA 1 and IDOL 1 correspond to two chemical species partially sharing the same physical space. The active transport with Michaelis-Menten type kinetics is characterized by the apparent maximal transport rates V max,12 and the apparent Michaelis constant K M,12 , and the k ij denote first order rate constants describing passive intercompartmental transport. Since the time course IDA 2 (t) was closely related to its pharmacodynamics (negative inotropy), it has been suggested that Compartment 2 reflects distribution in cardiomyocytes (Weiss and Kang, 2002) . The rate constant k 24 accounts for cellular sequestration (irreversible binding and/or conversion to IDA aglycone). An unexpected feature of the model is the finding that IDOL is produced in two compartments, IDA 1 and IDA 2 , with metabolism rate constants k m,1 and k m,2 , respectively. (Simpler models had to be rejected because they did not account for the double-peak shape of the IDOL outflow profile.) Interestingly, cardiac disposition of the generated IDOL was very similar to that of the parent compound, including the MichaelisMenten like re-uptake process.
Additional to the experiments described above, we have analyzed the IDOL data of the 10-min infusion experiment (Weiss and Kang, 2002) . Besides a verification of the model for a different input rate of IDA, we were interested in the effect of P-glycoprotein inhibitors on IDOL disposition. Similarly as described above, parameter estimates were obtained by simultaneous nonlinear regression of the average data in the control, verapamil, and amiodarone groups.
The fraction of IDA and IDOL recovered in outflow perfusate at the end of experiment [A R (t last )/Dose, t last ϭ 80 min] was calculated model-independently from the outflow concentration versus time data, C(t), and perfusate flow, Q, using a numerical integration method as
Statistics. The outflow data are presented as mean Ϯ S.D. Statistical significance was assessed with an analysis of variance followed by StudentNewman-Keuls test using the SigmaStat program (SPSS Science Inc., Chicago, IL). A value of P Ͻ 0.05 was considered statistically significant. The likelihood ratio test (Huet et al., 1996) was used to determine the significance of parameter changes in the nested models due to the presence of metabolism inhibitors (rutin and phenobarbital) or P-gp inhibitors (verapamil and amiodarone).
Results
Kinetics of IDOL Formation and Disposition. The outflow concentration of IDOL generated by the heart after the 1-min infusion of 0.5 mg of IDA was much lower (peak approximately 3 orders of magnitude) than that of the parent drug (Fig. 2, A and B) . The IDOL outflow profiles display a characteristic double peak shape; after the initial peak at the end of IDA infusion, the curves decay rapidly within 10 s before reaching the second peak at about 10 min (Fig. 3C ). This behavior implies the assumption of an additional site of metabolism (Compartment IDA 1 ) besides the expected formation of IDOL in cardiomyocytes (Compartment IDA 2 ). The minimal model (Fig. 1 ) allowed a reasonable fit of IDA and IDOL outflow data (Fig. 3 , A and C). As previously shown for IDA (Weiss and Kang, 2002; Kang and Weiss, 2003) , the re-uptake of IDOL is characterized by a saturable, Michaelis-Menten type process (maximal transport rate V max,IDOL , 3.2 nmol/min; apparent Michaelis constant K M,IDOL , 0.24 nmol). The parameter estimates are summarized in Table 1 .
Effects of Rutin and Phenobarbital on Pharmacokinetics of IDA and IDOL. In the presence of metabolic inhibitors, the outflow concentration of IDA and IDOL is reduced during the terminal washout phase (Fig. 2, A and B) . The average outflow recoveries and residual amounts in the heart at 80 min for IDA and IDOL in the absence and presence of rutin (10 M) or phenobarbital (100 M) are depicted in Fig. 2 , C and D, respectively. Rutin increases the residual amount of IDA in the heart at the end of experiment ϳ1.4-fold (P Ͻ 0.05). Phenobarbital and rutin induced a decrease in residual amount of IDOL to 47% (P Ͻ 0.05) and 32% (P Ͻ 0.05) of control, respectively. Rutin also decreased IDOL recovery into perfusate by 69% (P Ͻ 0.01).
Good fits of IDA and IDOL outflow curves in the presence of metabolic inhibitors were obtained (Fig. 3) and relatively low fractional standard deviations were associated with the estimated parameters (Table 1) . Rutin and phenobarbital decrease the cellular formation rate constant of IDOL (k m,2 ) to 67% (P Ͻ 0.05) and 80% of the control, respectively. The 2-fold increase in sequestration rate (k 24 ) of IDA in the presence of rutin (P Ͻ 0.01) explains the increase in residual amount of IDA in the myocard. Phenobarbital competitively
FIG. 1. The kinetic model for the description of cardiac formation and disposition of IDOL generated from IDA (indicated in bold).
First order rate constants are denoted by k ij (k 1m and k 2m are the formation rate constants of metabolite). The Michaelis-Menten like transport processes are characterized by parameters V max,ij and K m,ij .
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at ASPET Journals on June 26, 2017 dmd.aspetjournals.org inhibits the uptake of IDA and IDOL (K M,12 and K M,IDOL increase by a factor of 1.7 and 2.3, respectively). The model predictions shown in Fig. 4 demonstrate that the myocardial amount of IDOL (which approaches the amount sequestrated into Compartment 3), is remarkably reduced in the presence of rutin or phenobarbital.
IDOL Pharmacokinetics after 10-min Infusion of IDA: Effects of Verapamil and Amiodarone. Figure 5 , A and B, shows the fits of average outflow concentration-time profiles for IDOL obtained from a 10-min infusion of IDA (0.5 mg) in the absence (n ϭ 5) and presence of verapamil (1 nM) and amiodarone (1 M, n ϭ 5), respectively. As for the 1-min infusion, the model (Fig. 1) allowed a reasonable prediction of the outflow concentration of the generated IDOL. Note that the peak concentration of IDOL (Fig. 5A) is by a factor of 0.004 less than that of IDA (Weiss and Kang, 2002) . A comparison with Fig. 3C shows that the initial peak becomes less pronounced if the input rate decreases; it nearly disappears for 10-min infusion of IDA (Fig. 5A) . Both verapamil and amiodarone lead to a parallel downward shift. As previously shown for IDA, the saturable re-uptake of IDOL is also enhanced by P-gp inhibitors: verapamil (Fig. 5A ) and amiodarone (Fig. 5B) increase V max,IDOL by a factor of 1.6 (P Ͻ 0.01) and 1.2, respectively. The model parameters characterizing the formation and disposition of IDOL in the 10-min experiments are listed in Table 2 .
Effect of Rutin and Phenobarbital on IDA Pharmacodynamics. Rutin (10 M) and phenobarbital (100 M) do not show any significant effect on IDA-induced cardiac performance (including its negative inotropism) except a change in coronary vascular resistance (CVR), which is depicted in Fig. 6 . The maximal vasoconstrictive effect of IDA is significantly reduced by rutin (22.3%, P Ͻ 0.05) and also the secondary increase in CVR during the washout phase is inhibited (P Ͻ 0.05). Phenobarbital, in contrast, potentiates this secondary phase of IDA induced vasoconstriction (nearly 2-fold at 80 min, P Ͻ 0.05)
Discussion
Pharmacokinetics. From the model independent results it follows 1) that about 2 and 8% of the IDA dose were metabolized to IDOL in the 1-and 10-min infusion experiments, respectively, and 2) that the Panels C and D, recovery of IDA and IDOL in perfusate and amount in heart at 80 min in hearts perfused with buffer (control), phenobarbital and rutin (mean Ϯ S.D., n ϭ 5; ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01, compared with control). Control data from a previous publication (Kang and Weiss, 2001) .
MYOCARDIAL METABOLISM OF IDARUBICIN TO IDARUBICINOL
at ASPET Journals on June 26, 2017 dmd.aspetjournals.org Downloaded from reduction of the residual amount of IDOL in the presence of 100 M phenobarbital was greater than the effect of 10 M rutin (Fig. 2D) . It is conceivable that because of nonlinear (concentration-dependent) cardiac uptake of IDA, the formation of IDOL is reduced when the same IDA dose is infused with higher rate (leading to higher input concentrations). Note that the total recovery is not complete since the formation of nonpolar products, aglycones, represents a second major metabolic pathway of IDA metabolism (about 30% of dose not recovered as IDA) (Loveless et al.,1978) An objective of the mathematical modeling is to determine what can be learned about the cardiac kinetics in terms of compartmentation of IDOL formation and the transport processes of IDA and IDOL. The parsimony principle of system identification states that the model should not be more complicated than necessary for the description of the data. We tried 15 models and rejected those that did not fit the experiment. The model was then selected as the simplest model that was in accordance with the data. As shown in Figs. 3 and 5, the model predictions and experimental observations of IDOL outflow concentration agree reasonably well for two different IDA input rates (0.5 mg in 1 and 10 min, respectively). However, the set of equations used for simulation is not exclusive and other kinetic expressions may also lead to reasonable results. Fortunately, apart from the goodness of fit, it is encouraging that the model accounts for the typical shape of the outflow curves (double peak) in case of the 1-and 10-min infusion experiments. Thus, the most likely reason for the appearance of the early IDOL peak was the generation of IDOL in a readily accessible compartment, besides its formation by cytosolic carbonyl reduction (Minotti et al., 1995; Licata et al., 2000) located in Compartment 2. One may speculate that the contribution of Compartment 1 reflecting the initial distribution of IDA arises from the carbonyl reductase in the vascular wall. (Note that the apparent initial distribution volume V 1 also accounts for rapid distribution processes and has no direct anatomical meaning.) Although such a localization was observed in human tissues (Wirth and Wermuth, 1992) , nothing is known on the function of the enzyme. Furthermore, we have evaluated the model with experimental data collected during conditions of inhibition of transport and metabolism. We found that these conditions altered the parameter estimates in a manner consistent with pharmacological expectations. This suggests but not directly demonstrates the validity of the underlying model. Several predictions result from the model: first, the longer compartmental residence time of IDOL resulting from its lower cellular efflux rate constant, k 21,IDOL , (compared with IDA) suggests a greater cardiac accumulation of the alcohol metabolite (Matis et al., 1985) ; second, the model confirms that rutin and phe- nobarbital reduce the rate constants for myocardial IDOL production (to 67 and 80% of control, respectively); and third and unexpectedly, phenobarbital inhibits the saturable uptake of IDA and IDOL (ϳ1.7-and 2.3-fold increase in K m ), which may also explain the lower myocardial retention of IDOL in the phenobarbital group. Although this observation appears to be consistent with phenobarbitalassociated inhibition of carrier-mediated drug transport, only an impairment of biliary excretion of some organic anions by phenobarbital has been reported so far (Studenberg and Brouwer, 1992) . (For acetaminophen glucuronide, this effect has been recently attributed to inhibition of Mrp2 by a phenobarbital metabolite (Xiong et al., 2002) ). Fourth, the enhancement of the IDOL re-uptake into Compartment 2 by the P-glycoprotein inhibitors verapamil and amiodarone (increase in V max ) is similar to that reported for IDA (Weiss and Kang, 2002) . This is in principal accordance with the action of multidrug resistant modulators on IDOL concentration in tumor cells (Schroder et al., 2000; Smeets et al., 2001 ) and suggests that P-glycoprotein inhibitors may also enhance the cardiac accumulation of IDOL. The physiologic role of cardiac P-glycoprotein expression and pharmacokinetic consequences of P-glycoprotein inhibition have been addressed previously (Weiss and Kang, 2002 ; and the references cited therein).
To further understand the effect of rutin and phenobarbital on the myocardial retention of generated IDOL, the time courses of total amount of IDOL in the heart (sum of all compartmental amounts) and in Compartment 3 were predicted. The simulation showed that both metabolic inhibitors effectively reduced the accumulation of IDOL and that at the end of the sampling interval (80 min) IDOL (and its metabolites) is nearly completely sequestered into Compartment IDOL 3 (Fig. 4) .
It should be noted that with the present approach one cannot differentiate uniquely between binding and transport processes; due to the high membrane binding and rapid drug distribution the estimated apparent initial distribution volume is input rate dependent, which leads to differences in the parameter estimates obtained in the 1-and 10-min infusion experiments. Furthermore, the generality of parameter estimates may be limited since, as pointed out above, it was absolutely necessary to describe IDA and IDOL kinetics by a minimal number of nonlinear transport processes. Despite these confounding effects and the fact that the role of intracellular compartments as well as of some parameter alterations (e.g., k 24 in the rutin and k 32 in phenobarbital group) cannot be readily interpreted in terms of specific transport or binding processes, kinetic modeling allows further quantitative understanding of cardiac metabolism of anthracyclines. However, the picture is not unique, and the conclusions of our analysis are only as good as the validity of the assumptions underlying the model. Pharmacodynamics. Here we are concerned with the effects of rutin and phenobarbital on the IDA-induced change in CVR. It has been suggested that the vasoconstriction produced by IDA may be due to an inhibition of nitric oxide (NO) synthesis (see Kang and Weiss, 2001 and references cited therein). In principle, our observation that rutin reduced the IDA-induced increase in CVR and nearly abolished the secondary rise in CVR during the washout phase (Fig. 6 ) is in accordance with the coronary vasodilator effects of this compound (Schussler et al., 1995) . However, the fact that in the present study rutin was used in a concentration that did not affect baseline coronary flow and that the IDA-mediated vasoconstriction has been attributed both to a reduction of nitric oxide production and increased inactivation by the formed superoxide (Garner et al., 1999) suggests that this effect of rutin can be explained by its free radical scavenging action. This mechanism was also supposed for the reversal by melatonin of the doxorubicin-induced coronary vasoconstriction (Liu et al., 2002) . The potentiation by phenobarbital of the secondary vasoconstrictor response, on the other hand, could be explained by an inhibition cGMP-mediated endothelium-dependent and independent vasorelaxations (Gerkens, 1987; Terasako et al., 1994) . Interestingly, the initial rapid vasoconstriction (which parallels the IDA outflow concentration profile) was not affected by phenobarbital. In view of the low fraction of IDOL (2%) generated from IDA, a significant contribution of IDOL to the pharmacodynamic effects of IDA is very unlikely in these experiments. Thus, the observed effects of rutin and phenobarbital on IDA pharmacodynamics cannot be explained by their inhibitory action on cardiac IDOL formation. Notably, no influence of rutin and phenobarbital on the time course of IDA-induced negative inotropism could be detected.
In summary, in this study, we have developed a kinetic model for characterizing the cardiac formation and disposition of the alcohol metabolite IDOL by simultaneous analysis of the outflow concentration-time profiles of IDA and IDOL. The ability of the model to fit the outflow curves of IDOL over a range of perfusate flow and in the presence and absence of carbonyl reductase inhibitors is encouraging with respect to the interpretation of estimated model parameters. We suggest that kinetic models of this kind provide valuable tools to bridge the gap between studies at the in vitro level and in intact organs.
